303 Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients With Vitiligo
Recommended Citation
Rosmarin D, Pandya AG, Grimes P, Lebwohl MG, Gottlieb AB, Hamzavi I, Butler K, Wei S. 303 Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients With Vitiligo. J Invest Dermatol 2022; 141(10):S201.
Document Type
Conference Proceeding
Publication Date
3-11-2022
Publication Title
J Invest Dermatol
Keywords
chemokine, CXCL9 chemokine, endogenous compound, gamma interferon inducible protein 10, interleukin 15, Janus kinase, Janus kinase 2 inhibitor, ruxolitinib, adult, clinical article, clinical trial, conference abstract, controlled study, drug therapy, drug withdrawal, exploratory research, face, female, follow up, gene expression, human, human tissue, male, phase 2 clinical trial, protein blood level, protein expression, randomized controlled trial, vitiligo
Abstract
Treatment with ruxolitinib cream (Janus kinase [JAK] 1/JAK2 inhibitor) in adult patients with vitiligo resulted in substantial repigmentation over 52 weeks in a phase 2 dose-ranging study (NCT03099304). We assessed maintenance of repigmentation among responders from the phase 2 study following ruxolitinib discontinuation after 104 weeks of treatment. Patients initially randomized to ruxolitinib cream (1.5% twice daily [BID], 1.5% once daily [QD], 0.5% QD, or 0.15% QD) with evidence of facial repigmentation at Week 24 who completed ≥1 follow-up visit 1, 3, or 6 months after an additional 52 weeks of 1.5% ruxolitinib cream BID (Weeks 52–104) were analyzed. Loss of repigmentation was defined as an increase in Vitiligo Area Severity Index score during the last follow-up visit vs Week 104 on ruxolitinib cream. The analysis included 16 patients (1.5% BID, n=3; 1.5% QD, n=5; 0.5% QD, n=3; 0.15% QD, n=5 [including 2 patients rerandomized to 1.5% BID/0.5% QD after Week 24]). Twelve patients (75.0%) maintained total body repigmentation and 13 (81.3%) maintained facial repigmentation during follow-up of 1–6 months; no patients from the 1.5% ruxolitinib BID treatment group (with 2 years’ exposure) experienced repigmentation loss. There were no significant differences in baseline serum levels of chemokine (C-X-C motif) ligand (CXCL) 9, CXCL10, or interleukin-15 in patients who experienced loss vs maintenance of repigmentation after ruxolitinib cream discontinuation. This exploratory analysis suggests that some repigmentation with ruxolitinib cream may be maintained post-discontinuation; larger follow-up studies are required to confirm these findings.
Volume
141
Issue
10
First Page
S201
